Fri, Jan 30, 2015, 9:37 AM EST - U.S. Markets close in 6 hrs 23 mins


% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • desert_dweller93 desert_dweller93 Jan 22, 2013 10:28 PM Flag

    ASCO GI abstract for ASG-5ME

    Abstract is out for the phase 1 study for pancreatic cancer.

    A phase I study of ASG-5ME, a novel antibody-drug conjugate, in pancreatic ductal adenocarcinoma

    .....Thus, 1.2 mg/kg was identified as the MTD and expanded (N=18). The most common AEs observed at the MTD were fatigue (50%), vomiting (44%), decreased appetite (39%), nausea (33%), and abdominal pain (33%); Grade 3 or 4 toxicities at the MTD included fatigue (28%), abdominal pain (22%), vomiting (17%), and neutropenia (17%). Antitumor activity was observed: 1 pt achieved an unconfirmed PR and 12 pts achieved SD. Five patients (14%) had reductions in CA19-9. Serum ASG-5ME exposures were approximately dose proportional. Of 23 pts with archived biopsies available for IHC analysis, 100% expressed SLC44A4 and 15 pts (65%) had high expression. Conclusions: ASG-5ME treatment was generally well tolerated in metastatic PDA pts, with preliminary evidence of antitumor activity. Further study of ASG-5ME in SLC44A4-expressing malignancies is warranted. Clinical trial information: NCT01166490.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
31.72+0.22(+0.70%)9:36 AMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.